107 related articles for article (PubMed ID: 18380989)
1. Prevalence of delayed clinician response to elevated prostate-specific antigen values.
Nepple KG; Joudi FN; Hillis SL; Wahls TL
Mayo Clin Proc; 2008 Apr; 83(4):439-45. PubMed ID: 18380989
[TBL] [Abstract][Full Text] [Related]
2. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
3. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
[TBL] [Abstract][Full Text] [Related]
4. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population?
O'Kelly F; Thomas A; Murray D; Galvin D; Mulvin D; Quinlan DM
Prostate; 2013 Sep; 73(12):1263-9. PubMed ID: 23657938
[TBL] [Abstract][Full Text] [Related]
5. Delayed clinician responses to elevated prostate-specific antigen values.
Sinsky T; Sinsky C; Wahls TL
Mayo Clin Proc; 2008 Aug; 83(8):961-2; author reply 962. PubMed ID: 18674482
[No Abstract] [Full Text] [Related]
6. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
7. Practice patterns of urologists in managing Korean men aged 40 years or younger with high serum prostate-specific antigen levels.
Yoo DS; Woo SH; Cho S; Kang SH; Kim SJ; Park SY; Lee SH; Jeon SH; Park J
Urology; 2014 Jun; 83(6):1339-43. PubMed ID: 24726151
[TBL] [Abstract][Full Text] [Related]
8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
9. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.
Issa MM; Zasada W; Ward K; Hall JA; Petros JA; Ritenour CW; Goodman M; Kleinbaum D; Mandel J; Marshall FF
Cancer Detect Prev; 2006; 30(3):269-75. PubMed ID: 16844319
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
12. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
13. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
14. Abnormal PSA tests--delays in referral.
Stapleton AM; Johns RL; Kopsaftis T; Tamblyn DJ; Pinnock CB
Aust Fam Physician; 2008; 37(1-2):84-8. PubMed ID: 18239761
[TBL] [Abstract][Full Text] [Related]
15. Trends in prostate-specific antigen testing from 1995 through 2004.
Farwell WR; Linder JA; Jha AK
Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
18. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
19. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
Porter MP; Stanford JL; Lange PH
Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]